Related Experiment Video
Updated: Apr 19, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.9K
How I use fibrinogen replacement therapy in acquired bleeding
Jerrold H Levy1, Lawrence T Goodnough2
1Department of Anesthesiology and Department of Surgery, Duke University School of Medicine, Durham, NC; and.
Blood
|December 19, 2014
Summary
Fibrinogen replacement therapy is crucial for managing bleeding patients with acquired coagulopathies. Studies support using fibrinogen concentrates or cryoprecipitate, guided by point-of-care testing for optimal hemostasis.
Area of Science:
- Biochemistry
- Hematology
- Critical Care Medicine
Background:
- Fibrinogen is essential for hemostasis and clot formation.
- Current transfusion guidelines offer variable recommendations for fibrinogen levels in bleeding patients.
- Acquired coagulopathies necessitate effective fibrinogen management.
Observation:
- Fibrinogen replacement therapy, using cryoprecipitate or fibrinogen concentrates, is increasingly supported by research.
- Clinical practice for fibrinogen administration varies based on product availability and regulatory status.
- Animal models and clinical trials demonstrate the importance of fibrinogen repletion in bleeding patients.
Findings:
- Fibrinogen concentrate therapy shows promise in restoring hemostasis.
- Point-of-care testing is vital for guiding timely fibrinogen replacement.
- Effective fibrinogen management is critical in diverse clinical scenarios.
Implications:
- Fibrinogen therapy is a key element in multimodal strategies for coagulopathic bleeding.
- Optimizing fibrinogen levels can improve outcomes in surgery, postpartum hemorrhage, and trauma.
- Further research will refine the role of fibrinogen repletion in critical care.
More Related Videos
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
475
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
475
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:16Clot Retraction and Fibrinolysis
10.6K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.6K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
16.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
16.2K
01:05Introduction to Hemostasis
19.5K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
19.5K
01:24Disorders of Hemostasis
2.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.9K